Solis Women’s Health Names Chet Dye CDO
ADDISON, TX – May 2, 2012 – Solis Women’s Health, the nation’s largest independent provider of screening and diagnostics for breast cancer, is pleased to announce that Chet Dye has been appointed Chief Development Officer (CDO).
Working closely with Solis CEO James Polfreman and COO Rick Pence, Mr. Dye will drive the company’s business growth in existing markets and new markets, with a particular emphasis on partnering with hospitals to elevate their women’s health initiatives, as Solis continues to expand its nationwide network of clinics devoted exclusively to the screening and diagnosis of breast cancer, which currently serves over 500,000 patients in five states.
“Chet has an exemplary track record of successfully expanding and exponentially increasing revenues for multi-location, alternative site healthcare companies,” said Solis Chairman Matthew Witte. “We are extremely pleased that he will be bringing his experience and relationships to Solis as we look to double our footprint of 23 clinics over the next 2 -3 years.”
Prior to assuming the position of CDO at Solis, Mr. Dye was National Vice President responsible for business development, sales, account management and physician recruiting for McKesson Specialty Health, a $7B pharmaceutical distributor and medical supplies distributor. In 2011, McKesson acquired US Oncology, a $3.3B firm providing management and support services to oncology practices and radiation treatment centers throughout the US. Mr. Dye served with US Oncology for 14 years in various capacities, including Vice President of Business Development and Physician Recruiting, Regional Vice President Business Development, Regional Director of Business Development and Regional Director of Managed Care. In his various capacities, Mr. Dye developed numerous new regional markets, completed six new hospital joint ventures, led the development of 21 new cancer centers in 6 states and launched the company’s first PET/CT imaging initiative adding 16 installations. He also facilitated and led numerous strategic planning sessions with US Oncology affiliated practices. Prior to US Oncology, Mr. Dye worked in sales and business development roles at Matria Healthcare, Astra Pharmaceuticals, Mobley Company, LIFO Systems and G&K Services.
Mr. Dye holds a Bachelor of Business Administration from Abilene Christian University in Texas.
“Chet has a keen ability to understand the needs of both new markets and business development teams in order to best promote expansion and rapid growth,” said Solis CEO, James Polfreman. “His proven ability to work through the challenges of acquisitions while never losing sight of service quality nor revenue goals was a key factor in bringing Chet on board. We look forward to having him on our team as we continue to offer exceptional breast care to women nationwide.”
With evidence that annual mammograms are effective in detecting breast cancer in its earliest stages, Solis Women’s Health was established to provide the highest standard of care and services in a positive atmosphere. The company was founded on the premise that by focusing exclusively on the detection of breast cancer, employing only experienced fellowship-trained breast physicians and utilizing state-of-the-art digital equipment, it can produce significantly better outcomes.
ABOUT SOLIS WOMEN’S HEALTH
Solis Women’s Health is a specialized healthcare provider focused exclusively on the screening and diagnosis of breast cancer. Headquartered in Addison, Texas, Solis currently operates 23 clinics in Dallas, Ft. Worth, Phoenix, Tucson, Indianapolis, Columbus, Ohio; and Greensboro, N.C. Solis provides a complete range of breast health services including screening and diagnostic mammography, computer-aided detection, breast ultrasound, automated breast ultrasound, bone densitometry, stereotactic and ultrasound-guided biopsy, breast specific gamma imaging and breast MRI. For more information, visit www.SolisHealth.com.
Gregory M. Scott
Vice President, Business Development
Solis Women’s Health